An observational study in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-24.
Sponsored by Boehringer Ingelheim · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim — 3 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Boehringer Ingelheim.
Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, this one is the 9th largest by enrollment of the 16 observational ones that give a count, is one of 5 that started in 2017, is one of 16 observational ones, and was the 56th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →3 of the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States, Australia, Austria and 15 more countries
Ages 18+
Boehringer Ingelheim · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 160 across 1,150 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 44 across the 49 interventional studies, 216 across the 16 observational. Of the 60 that completed or were terminated, 53 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
1 of the studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05708599Boehringer IngelheimA Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer | 2027-02-08 |
Add it to your calendar (.ics) → With an account.
Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line treatment followed by osimertinib in case the T790M resistance mutation was developed.
Study is planned that around 65 study centres in 11 countries will be participating in this noninterventional study and at least 190 consecutive eligible patients will be enrolled to the study. Every patient who fulfils inclusion and exclusion criteria and agree to participate in the study (if a written informed consent is required for this NIS by local regulation and legal requirement) will be selected until the required sample size is achieved.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)
Drug: Afatinib · Drug: Osimertinib
GILOTRIF, GIOTRIF, XOVOLTIB
on T790M resistance mutation was developed
Time on Treatment With Afatinib (Gi(l)Otrif®) Followed by Osimertinib
Time on treatment, which was defined as time in months from the start date of Afatinib (Gi\[l\]otrif®) treatment ('start date of initial dose' for First-Line Treatment) to the end date of Osimertinib treatment (maximum between 'end date of initial dose' and the last 'end date of dose modification' for Second-Line Treatment) or death date due to any cause ('date of death'). Time on treatment (months) = Time on treatment (days)/30.4375. 'Time on treatment was analysed using Kaplan-Meier method, and the median along with two-sided 90% confidence interval was displayed using the Greenwood's formula for estimation of standard errors.
Time frame: Data collected from start of treatment until data entry completion, up to 96.8 months for first analysis and up to 114.1 months for the extension analysis.
The Percentage of Participants With Different Types of Mutations After Categorisation
Different types of resistance mutations identified at the time of discontinuation of osimertinib treatment were systematically reviewed and categorised.
Time frame: Data collected from start of treatment until data entry completion; up to 96.8 months.
Non-interventional, multi-centre cohort study based on existing data from medical records of patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC) treated with afatinib (Gi\[l\]otrif®) as first-line treatment followed by osimertinib in case the T790M resistance mutation was developed. The study included an extension analysis using additional collected data of the enrolled patients.
| Milestone | Patients With EGFR Mutation-positive NSCLC |
|---|---|
| Started | 204 |
| Completed | 98 |
| Not completed | 106 |
| Withdrew: Patient was followed in another hospital center | 1 |
| Withdrew: Progressive disease | 98 |
| Withdrew: Adverse event | 2 |
| Withdrew: Death | 5 |
Time on treatment, which was defined as time in months from the start date of Afatinib (Gi\[l\]otrif®) treatment ('start date of initial dose' for First-Line Treatment) to the end date of Osimertinib treatment (maximum between 'end date of initial dose' and the last 'end date of dose modification' for Second-Line Treatment) or death date due to any cause ('date of death'). Time on treatment (months) = Time on treatment (days)/30.4375. 'Time on treatment was analysed using Kaplan-Meier method, and the median along with two-sided 90% confidence interval was displayed using the Greenwood's formula for estimation of standard errors.
| Months | Patients With EGFR Mutation-positive NSCLC |
|---|---|
| First analysis | 27.6 (25.9 to 31.3) |
| Extension analysis | 27.7 (26.7 to 29.9) |
Different types of resistance mutations identified at the time of discontinuation of osimertinib treatment were systematically reviewed and categorised.
| Percentage of participants (%) | Patients With EGFR Mutation-positive NSCLC |
|---|---|
| T790M positive | 69.2 |
| Loss of T790M | 20.5 |
| T790M positive, loss of sensitizing mutation | 10.3 |
Collected over Adverse event information was not applicable for this study, as data were collected retrospectively. The approach was changed for the extension period: Adverse Events were collected from start of data collection once informed consent was signed onwards until the end of data collection, up to 18 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients With EGFR Mutation-positive NSCLC | 31/203 (15.3%) | 32/203 (15.8%) | 62/203 (30.5%) |
| Event | Patients With EGFR Mutation-positive NSCLC |
|---|---|
| Disease progressionGeneral disorders | 27/203 |
| DeathGeneral disorders | 1/203 |
| DiarrhoeaGastrointestinal disorders | 1/203 |
| SepsisInfections and infestations | 1/203 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/203 |
| RashSkin and subcutaneous tissue disorders | 1/203 |
| Event | Patients With EGFR Mutation-positive NSCLC |
|---|---|
| DiarrhoeaGastrointestinal disorders | 52/203 |
| RashSkin and subcutaneous tissue disorders | 34/203 |
| ParonychiaInfections and infestations | 25/203 |
| StomatitisGastrointestinal disorders | 21/203 |
| DermatitisSkin and subcutaneous tissue disorders | 12/203 |
Full Analysis Set (FAS): FAS included all patients who were enrolled into the study, met all inclusion criteria and did not meet any exclusion criteria and provided a written and signed informed consent (if a written informed consent was required for this NIS by local regulation and legal requirement).
| Age, Continuous(Years) | Patients With EGFR Mutation-positive NSCLC |
|---|---|
| Mean | 60.1 ± 10.48 |
| Sex: Female, Male(Participants) | Patients With EGFR Mutation-positive NSCLC |
|---|---|
| Female | 110 |
| Male | 94 |
| Ethnicity (NIH/OMB)(Participants) | Patients With EGFR Mutation-positive NSCLC |
|---|---|
| Hispanic or Latino | 19 |
| Not Hispanic or Latino | 181 |
| Unknown or Not Reported | 4 |
| Race (NIH/OMB)(Participants) | Patients With EGFR Mutation-positive NSCLC |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 50 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 18 |
| White | 120 |
| More than one race | 0 |
| Unknown or Not Reported | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2017 to primary completion in Nov 2019, 23 months.
Results were first posted in Dec 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →